Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT.

IF 3.6 3区 医学 Q2 HEMATOLOGY
Vanessa E Kennedy, Nausheen Ahmed, Andy Artz, Neel S Bhatt, Rachel Custatis, Manuel R Espinoza-Gutarra, Shatha Farhan, Robert J Ferguson, Betty Hamilton, Hannah Katz, Debra L Kelly, Jennifer M Knight, Catherine Lee, Adam Lin, Richard Lin, Lathika Mohanraj, Pashna Munshi, Mariam Nawas, Ashley M Nelson, Silvina Odstracil, Rebecca Olin, Rachel Phelan, Kelly E Rentscher, Hélène Schoemans, Anthony Sung, Mallory R Taylor, Wiliam Wood, Carrie H Yuen, Reena V Jayani-Kosarzycki
{"title":"Assessing Cognitive Function in Transplantation and CAR-T Recipients: Expert Recommendations from the Survivorship, Aging and Biobehavioral Special Interest Groups of ASTCT.","authors":"Vanessa E Kennedy, Nausheen Ahmed, Andy Artz, Neel S Bhatt, Rachel Custatis, Manuel R Espinoza-Gutarra, Shatha Farhan, Robert J Ferguson, Betty Hamilton, Hannah Katz, Debra L Kelly, Jennifer M Knight, Catherine Lee, Adam Lin, Richard Lin, Lathika Mohanraj, Pashna Munshi, Mariam Nawas, Ashley M Nelson, Silvina Odstracil, Rebecca Olin, Rachel Phelan, Kelly E Rentscher, Hélène Schoemans, Anthony Sung, Mallory R Taylor, Wiliam Wood, Carrie H Yuen, Reena V Jayani-Kosarzycki","doi":"10.1016/j.jtct.2025.06.026","DOIUrl":null,"url":null,"abstract":"<p><p>Cognitive impairment is a prevalent yet underexplored comorbidity and complication in hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy. Affecting up to half of patients, cognitive impairment may include acute phases, manifesting as transplant-associated altered mentation and encephalopathy (TAME) or immune effector cell-associated neurotoxicity syndrome (ICANS), and may persist for years post-treatment as cancer-related cognitive impairment (CRCI). Such dysfunction undermines autonomy, healthcare management, work reintegration, and quality of life. This consensus review synthesizes current evidence on CRCI across the timeline of transplant and cellular therapy, organized into pre-, peri-, and post-therapy phases, with additional focus on specific populations, such as older adults and pediatric patients. It highlights gaps in understanding of cognitive impairment risks, trajectory, and impact, alongside the challenges of standardizing assessments in diverse practice settings. Key recommendations, endorsed by the American Society for Transplantation and Cellular Therapy (ASTCT) Aging, Biobehavioral Research, and Survivorship Special Interest Groups, advocate for cognitive assessment pre- and post-therapy using validated instruments, like the Montreal Cognitive Assessment (MoCA) or Blessed Orientation-Memory-Concentration Test (BOMC). We additionally recommend supplementing with patient-reported outcomes (PROs) measures for comprehensive evaluation. If cognitive impairment is identified, we recommend action items, including exclusion of alternative etiologies, reconsideration of therapy or caregiving plan, and referrals for additional evaluation and rehabilitation, among others. Practical guidance for implementation across clinical and research settings is provided, emphasizing the need for multidisciplinary strategies to address identified impairments. This work aims to establish a framework for systematic cognitive monitoring, improving patient outcomes and quality of life while guiding future research to address significant knowledge and implementation gaps.</p>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation and Cellular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtct.2025.06.026","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cognitive impairment is a prevalent yet underexplored comorbidity and complication in hematopoietic stem cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell therapy. Affecting up to half of patients, cognitive impairment may include acute phases, manifesting as transplant-associated altered mentation and encephalopathy (TAME) or immune effector cell-associated neurotoxicity syndrome (ICANS), and may persist for years post-treatment as cancer-related cognitive impairment (CRCI). Such dysfunction undermines autonomy, healthcare management, work reintegration, and quality of life. This consensus review synthesizes current evidence on CRCI across the timeline of transplant and cellular therapy, organized into pre-, peri-, and post-therapy phases, with additional focus on specific populations, such as older adults and pediatric patients. It highlights gaps in understanding of cognitive impairment risks, trajectory, and impact, alongside the challenges of standardizing assessments in diverse practice settings. Key recommendations, endorsed by the American Society for Transplantation and Cellular Therapy (ASTCT) Aging, Biobehavioral Research, and Survivorship Special Interest Groups, advocate for cognitive assessment pre- and post-therapy using validated instruments, like the Montreal Cognitive Assessment (MoCA) or Blessed Orientation-Memory-Concentration Test (BOMC). We additionally recommend supplementing with patient-reported outcomes (PROs) measures for comprehensive evaluation. If cognitive impairment is identified, we recommend action items, including exclusion of alternative etiologies, reconsideration of therapy or caregiving plan, and referrals for additional evaluation and rehabilitation, among others. Practical guidance for implementation across clinical and research settings is provided, emphasizing the need for multidisciplinary strategies to address identified impairments. This work aims to establish a framework for systematic cognitive monitoring, improving patient outcomes and quality of life while guiding future research to address significant knowledge and implementation gaps.

评估移植和CAR-T受体的认知功能:来自ASTCT存活、衰老和生物行为特殊兴趣小组的专家建议
认知障碍是造血干细胞移植(HCT)和嵌合抗原受体(CAR) t细胞治疗中普遍存在的合并症和并发症。影响多达一半的患者,认知障碍可能包括急性期,表现为移植相关的精神状态改变和脑病(TAME)或免疫效应细胞相关神经毒性综合征(ICANS),并可能在治疗后持续数年,表现为癌症相关的认知障碍(CRCI)。这种功能障碍会损害员工的自主权、医疗管理、重新融入工作和生活质量。本共识综述综合了移植和细胞治疗期间CRCI的现有证据,分为治疗前、治疗中和治疗后阶段,并特别关注特定人群,如老年人和儿科患者。它突出了对认知障碍风险、轨迹和影响的理解差距,以及在不同实践环境中标准化评估的挑战。由美国移植和细胞治疗学会(ASTCT)、衰老、生物行为研究和幸存者特殊兴趣小组支持的关键建议,提倡在治疗前和治疗后使用有效的工具进行认知评估,如蒙特利尔认知评估(MoCA)或幸福定向-记忆-集中测试(BOMC)。我们还建议补充患者报告的结果(PROs)措施进行综合评估。如果识别出认知障碍,我们建议采取行动,包括排除其他病因,重新考虑治疗或护理计划,以及转介进行额外的评估和康复等。提供了跨临床和研究设置实施的实用指导,强调需要多学科战略来解决已确定的缺陷。这项工作旨在建立一个系统的认知监测框架,改善患者的预后和生活质量,同时指导未来的研究,以解决重大的知识和实施差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
15.60%
发文量
1061
审稿时长
51 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信